- Insulin Markets in US, Europe, Japan, ROW - Oral Hypoglycemics in US, Europe, Japan, ROW
For each of these market segments the report provides market share and regional breakout (US, Europe, Asia, ROW). The report also discusses treatment for diabetes complications and natural and herbal treatments.
The report's geographic scope is worldwide with information for specific geographical regions; world demographics; life expectancy by country, and other general issues affecting the market. Trends covered in the report include:
- New Products and the Development Pipeline (Afrezza, Bydureon, Syncria, AVE0010, Balaglitazone, Metgluna Otelixizumab and others) - Transplantation Research Efforts - B-Cell Transplantation Research - Potential New Drug for Type 2 Diabetes - Insulin Pills - Three-month Insulin Shot - Outsourcing of Diabetes Projects - Reclassification of Cause of Death
Information is presented as a worldwide overview, with special emphasis on the U.S., Europe, and other key markets.
A market summary includes market analysis by product and region and a competitive analysis of leading providers. Additionally, key company profiles are included, including profiles of the following:
- Amylin Pharmaceuticals - AstraZeneca - GlaxoSmithKline - Eli Lilly & Co. - Merck - Metabolex, Inc. - Novo Nordisk A/S - Pfizer Inc. - Sanofi-Aventis Group - Takeda Pharmaceutical Company Limited
The information for this report was gathered using both primary and
secondary research including comprehensive resear
Copyright©2010 PR Newswire.
All rights reserved